



LAO PEOPLE 'S DEMOCRATIC REPUBLIC  
PEACE INDEPENDENCE DEMOCRACY UNITY PROSPERITY

MINISTRY OF HEALTH  
FOOD AND DRUG DEPARTMENT  
TEL ( 856 21 ) 214013, 214014  
FAX: ( 856 21 ) 214015.

## Certificate of Drug Registration

Registration Number:07-LM-10048-26

### ALIBIMETINI

|                        |                                                                                                                                |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Dosage Form            | <b>TABLET, FILM COATED</b>                                                                                                     |
| Active Ingredients     | <b>BINIMETINIB 15 mg</b>                                                                                                       |
| Description            | <b>This product is a Yellow film coated tablet, oval, HDPE Bottle, 90 tablets per bottle</b>                                   |
| Size of packaging unit | <b>90 TABLETS</b>                                                                                                              |
| Indications            | <b>See Annex</b>                                                                                                               |
| Manufacturer           | <b>LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY<br/>SAYSETHA DEVELOPMENT ZONE, SAYSETHA DISTRICT, VIENTIANE CAPITAL, LAO PDR</b> |

This Certificate is issued to attest that the product described above has met the minimum standards required for drug registration undertaken by the Food and Drug Department in Lao PDR.

This certificate expires, unless previously suspended or revoked, on **15 July 2031**

Note: All boxes and packaging for importations must bear the Lao Registration No. **07-LM-10048-26**

At, Vientiane, **15 July 2026**



ນ.ພຸດທະວັນ ອິນລໍຄຳ



Registration Number:07-LM-10048-26

## ALIBIMETINI

### ANNEX

#### INDICATIONS

Binimetinib is a kinase inhibitor indicated:

- in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
- in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.

Binimetinib ເປັນຢາຢັບຢັງ kinase inhibitor ສໍາລັບ:

ໃຊ້ຮ່ວມກັບ encorafenib ໃນການປິ່ນປົວຄົນເຈັບທີ່ເປັນມະເຮັງຜິວໜັງຊະນິດ ເມລາໂນມາ (Melanoma), ທີ່ບໍ່ສາມາດຜ່າຕັດໄດ້ ຫຼື ມີການແຜ່ລາມດ້ວຍການກາຍພັນຂອງ BRAF V600E ຫຼື V600K.

ໃຊ້ຮ່ວມກັບ encorafenib ໃນການປິ່ນປົວຄົນເຈັບຜູ້ໃຫຍ່ທີ່ເປັນມະເຮັງປອດຊະນິດ Non-small cell lung cancer (NSCLC) ໃນໄລຍະແຜ່ລາມ ທີ່ມີການກາຍພັນຂອງ BRAF V600E.